RedHill Biopharma Issued Key US Patents for Promising Crohn’s Disease Treatment Candidate

RedHill Biopharma Issued Key US Patents for Promising Crohn’s Disease Treatment Candidate
Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently announced its acquisition of two notices of allowance from the United States Patent and Trademark Office (USPTO) covering patient application numbers 13/722,395 and 14/271,758 for RHB-104, a novel antibiotic combination treatment in oral capsule form. The drug boasts an improved formulation that features enhanced intracellular, anti-mycobacterial and anti-inflammatory properties. At present,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *